The Pharmaceutical Industry’s Quiet Win in the One Big Beautiful Bill Act

The One Big Beautiful Bill Act benefits the pharmaceutical industry by limiting Medicare’s ability to negotiate drug prices, expanding tax breaks, and shrinking Medicaid coverage. These policy changes are expected to raise health care costs, reduce patient access, and weaken recent drug pricing reforms, prioritizing industry profits over public health and affordability.